The single-arm, nonrandomized phase IB study (MSC-COV-10) investigated the safety and preliminary efficacy of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) in treating COVID-19-induced acute respiratory failure or acute respiratory distress syndrome. COVI-MSCs were administered every other day for up to three infusions and a total of 1,000,000 cells/kg. Patients were followed for 28 days after the final infusion, and no infusion-related adverse events were observed, according to the company.

A pivotal placebo-controlled study is now being planned at multiple sites in the U.S. and Brazil to support an emergency use authorization submission, Sorrento said.

Sorrento advances anti-COVID-19 antibody combo from Mount Sinai
Sorrento Therapeutics and the Icahn School of Medicine at Mount Sinai have entered into an exclusive license agreement for a collection of antibodies...

Sorrento subsidiary to develop ADC cancer therapies
Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for...

Sorrento to file IND for anti-SARS-CoV-2 nasal drops
Sorrento Therapeutics is filing an investigational new drug application (IND) with the U.S. Food and Drug Administration for its STI-2099 (Covi-Drops),...

Sorrento plans phase II trial for COVID-19 treatment
Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment...

Sorrento moves forward with COVID-19 prophylactic drug
Sorrento has completed preclinical testing of STI-4398 (COVIDTRAP), reporting positive results on the protein's ability to neutralize and inhibit the...